Update: February 29, 2020 Aclaris Exits Hair Loss Business Recent rumors are, unfortunately, very true. Several days ago, I contacted Aclaris Therapeutics’ Head of Corporate Strategy Mr. Michael Tung. I asked him for any update on their androgenetic alopecia (AGA) JAK inhibitor product. His short and succinct response was as follows: “We exited all of … Continue reading An Overdue Aclaris Update→
Yesterday, Aclaris announced that their oral ATI-501 JAK 1/3 inhibitor Phase 2 clinical trials were successful in treating patients with alopecia areata (AA). No serious side effects reported. Not a huge surprise since JAK inhibitors have been proven to work well on alopecia areata patients in the past. But a relief after Aclaris’ topical ATI-502 … Continue reading Aclaris Therapeutics Oral JAK Inhibitor Success in Alopecia Areata→